Revolution Medicines: Advancing Late-Stage RAS Inhibitor Pipeline with Pivotal Phase 3 Catalysts Supports Buy Rating

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Revolution Medicines. The associated price target remains the same with $104.00.

Charles Zhu has given his Buy rating due to a combination of factors tied to Revolution Medicines’ advancing RAS inhibitor portfolio and clear clinical execution. He highlights the initiation and randomization of the Phase 3 RASolute 304 study in resectable pancreatic cancer as another meaningful proof point that the company is successfully expanding its late-stage pipeline. Zhu also underscores that multiple additional Phase 3 trials are either imminent or underway, including front-line pancreatic and lung cancer studies for daraxonrasib, as well as first-line efforts for zoldonrasib and potentially elironrasib, which together create a diversified set of registration-stage opportunities.
At the same time, Zhu points to the upcoming Phase 3 RASolute 302 data in second-line pancreatic cancer as the key near-term inflection for the stock, with the results expected to inform not only that specific indication but also the prospects of daraxonrasib in first-line pancreatic cancer. He views this readout as a major value-defining event that could validate the broader RAS strategy and unlock additional upside across the company’s programs. Overall, the combination of strong clinical momentum, a broad late-stage development plan, and a pivotal upcoming catalyst underpins his constructive stance and supports maintaining a Buy recommendation on RVMD.

In another report released on December 12, Wells Fargo also assigned a Buy rating to the stock with a $100.00 price target.

Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RVMD in relation to earlier this year.